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ABSTRACT 
In recent decades, efforts have been made to rationally design antimicrobial peptides (AMPs) for 
use as alternative therapeutics. The de novo designed AMP WLBU2 is a 24 residue long 
cationic, α-helical peptide. Antimicrobial activity of WLBU2 is predicted to be based on peptide 
interaction with lipid membranes leading to bilayer disruption. Antibacterial activity of WLBU2 
has been displayed against a wide-range of antibiotic resistant Gram positive and Gram negative 
bacteria based on charge interactions between the cationic peptide and the anionic bacterial 
membrane lipids. Preliminary experiments indicated WLBU2 has antiviral activity against 
various enveloped viruses suggesting the potential for development of a broad spectrum antiviral 
treatment. While viral envelopes do not have the same negative surface charge presumed to be 
the basis for antibacterial activity of WLBU2, most mammalian virus membranes are enriched 
for cholesterol relative to host cells. We hypothesized that specifically targeting WLBU2 to 
cholesterol rich membranes would increase antiviral activity against a broad range of enveloped 
mammalian viruses. Addition of the cholesterol recognition amino acid consensus (CRAC) motif 
is predicted to direct WLBU2 to cholesterol rich viral envelopes, thereby disrupting the 
membrane and leading to virus inactivation. When tested against human immunodeficiency virus 
(HIV), influenza A, and dengue virus (DENV), computationally designed CRAC motif 
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containing peptides and unmodified WLBU2 activity varied across the panel of viruses tested.  
Antiviral activity was observed against influenza A and DENV, and CRAC motif containing 
peptides were about 10-fold more effective against DENV than unmodified WLBU2. 
Therapeutic indices of CRAC motif containing peptides were similar to that observed for 
unmodified WLBU2. These findings suggest that AMPs can be designed to enhance antiviral 
activity, representing a novel therapeutic design with the potential for significant public health 
impact against global diseases such as influenza and DENV. 
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1.0  INTRODUCTION 
In the past decade, antimicrobial peptides (AMPs) have been considered for their 
potential as novel therapeutic agents against bacteria, viruses, and fungi. Naturally occurring 
AMPs are produced by animals and plants as important components of the first line of defense of 
the innate immune response (1; 2). They have evolved to respond to properties of microbes that 
are not dependent on metabolic activity, allowing for a broader range of antimicrobial activity 
based on general membrane properties that are similar between most microbial membranes (3). 
Because of this, AMPs have been designed, developed and tested for treatment against bacteria, 
viruses, fungi, and even cancer. 
1.1 NATURALLY OCCURRING ANTIMICROBIAL PEPTIDES 
While over 2000 AMPs have been identified from various plants and animals (4), some 
general properties have been observed that allow for peptides to disrupt or traverse membranes. 
AMPs are commonly made of fewer than 100 amino acids (32 amino acids average), have a net 
cationic charge, and form an amphipathic structure where positive residues segregate to one side 
and hydrophobic residues to the opposite (5). Almost all identified AMPs can be categorized into 
four major classes based on peptide structure: β-sheet, α-helical, extended, and loop peptides 
(Figure 1) (6). The range of AMP structures and sequences likely reflects the specialization of 
2 
each peptide to different environments in the body (7). In humans and other mammals, two of the 
most important classes of AMPs produced within the body are the defensins and cathelicidins 
which fall into the β-sheet and α-helical peptide structural classes, respectively. Defensins and 
cathelicidins are generally distributed throughout the epithelia and mucosa and are present 
constitutively at relatively high concentrations (8). Though structurally distinct, both defensins 
A. β-sheet peptides represented by the defensin human neutrophil protein-3 (10.2210/
pdb1zmh/pdb). B. α-helical peptides represented by the human cathcathelicidin hCAP-18/
LL-37 (10.2210/pdb2k6o/pdb). C. Extended peptides as represented by bovine indolicidin 
(10.2210/pdb1g89A/pdb). D. Loop peptides as represented by gramicidin dimer from 
Brevibacillus brevis (10.2210/pdb1bdw/pdb). All structures obtained from RCBS PDB 
(www.rcsb.org/pdb/home/home.do). 
Figure 1. The four major classes of antimicrobial peptides represented structurally by 
one member of each class. 
3 
and cathelicidins are important in the innate immune response to infection, as evidenced by their 
wide distribution and ubiquitous presence (8; 9).  
Most AMPs, including defensins and cathelicidins, exploit natural properties of target 
membranes to distinguish self from non-self and cause permeabilization of target membranes (3; 
10). The cationic charge and amphipathic structure of AMPs allow for specific targeting of 
foreign membranes based on differences in lipid composition, as best characterized by their 
antibacterial activity (10). The outermost leaflet of bacteria contains more anionic lipids than 
animal cell membranes, thus AMPs target bacterial membranes specifically based on surface 
charge. Once attracted to the foreign membrane, AMPs assume an amphipathic structure where 
hydrophobic residues insert into the membrane based on interactions with the non-polar tails of 
lipid bilayers (Figure 2). Peptide interaction with the membrane can lead to disruption through 
Initial contact between ordered lipid bilayer and AMP 
occurs through cationic residue interaction with phospholipid 
head. This interaction disrupts the membrane as hydrophobic 
residues insert into the bilayer disordering the membrane. This 
disorder allows peptide to either form pores in the membrane or 
cross into the cell. 
Figure 2. General mechanism of action for AMPs.
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various proposed mechanisms, including barrel-stave, carpet, and toroidal pore mechanisms (11). 
In each of these mechanisms, peptides aggregate in different conformations at the surface of the 
membrane and cause permeabilization through interaction of these peptide aggregates with the 
membrane surface.  Evidence towards each of these mechanisms exists, yet it does not appear 
that any one is specific to a particular peptide class (12). Further, it is possible that the same 
peptide could disrupt membranes through all of these mechanisms based on the interaction with a 
particular membrane (3). AMPs can then cause death or inactivation either by leading to efflux 
of ions and essential nutrients or by entering the cell and interacting directly with intracellular 
components (5). AMPs have even been considered for their potential as anticancer treatments 
based on these similar membrane targeting strategies (13; 14). AMPs have emerged as an 
attractive antimicrobial alternative because they target fundamental membrane characteristics 
that are difficult for bacteria, viruses, and fungi to alter and still remain viable and infectious. 
1.1.1 LL-37 
Since its initial discovery in 1994 (15), the human cathelicidin LL-37 has been 
extensively studied for its therapeutic potential in treating bacterial, viral, and fungal infections. 
This naturally occurring α-helical peptide is 37 amino acids long and is known to be an 
important component of mucosal immunity, most importantly in the lung (8). LL-37 also 
possesses various other functions including immune modulation, apoptosis, and chemotaxis (16). 
It is produced from a precursor peptide known as hCAP-18 by proteolysis in neutrophils, 
macrophages, and some epithelial cells (17). Antibacterial and antiviral activity against a broad 
range of pathogens has been demonstrated using LL-37 in in vitro culture conditions. Further, 
LL-37 has also demonstrated antiviral activity against various enveloped viruses, including 
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influenza A (18), herpesviruses (19), vaccinia (20; 21), human immunodeficiency virus (HIV) 
(22), adenovirus (23), and respiratory syncytial virus (RSV) (24) in vitro. In the case of influenza 
A, LL-37 likely exerts its antiviral activity by membrane disruption (25), whereas for HIV, it has 
been proposed that infection is blocked by direct interaction with reverse transcriptase, inhibiting 
replication (26). 
Despite the broad range of activity of LL-37, there are limitations to its use as a potential 
therapeutic. In in vitro studies, the antimicrobial activity of LL-37 varies widely based on 
conditions such as serum and salt concentrations, as well as pH (16). These conditions also vary 
across different environments in the body, indicating that LL-37 is best suited for activity within 
the lung and would be less effective in other parts of the body, such as the blood or 
gastrointestinal tract (8). Concentrations of LL-37 are elevated in the lungs of cystic fibrosis 
(CF) patients where there are chronic bacterial infections, leading to a persistent inflammatory 
environment (27). However, abnormally high salt concentrations, reduced airway surface pH 
(28), and complexation with glycosoaminoglycans (29) diminish the antimicrobial potential of 
LL-37 associated with the respiratory epithelium. Indeed, these deficiencies in LL-37 activity in 
the CF lung are thought to contribute to the ability of bacteria to easily colonize the lung. These 
observations indicate that the environments in which AMPs are naturally found affect the 
activity of those peptides. Due to the limitations of application for LL-37 as a potential 
antimicrobial, efforts have been made to design de novo AMPs that would have a similarly broad 
range of antimicrobial activity without the limitations observed in certain pH and salt conditions. 
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1.2 ENGINEERED CATIONIC ANTIMICROBIAL PEPTIDES – WLBU2 
Using observations of the properties of naturally derived AMPs, engineered cationic 
AMPs have been developed as therapeutics by multiple labs (30; 31; 32). In the past decade, our 
lab has been at the forefront of engineering AMPs based on structural and functional 
characteristics of host-derived peptides with potent antimicrobial activity (33; 34). Our lab 
previously designed and characterized a series of peptides based on the lytic base unit (LBU) of 
12 amino acids composed of arginine and valine (35). The LBU was designed to form an 
idealized amphipathic helix in which all cationic residues segregate to one side and all 
hydrophobic residues to the other. These peptides were also designed to take advantage of the 
cost effectiveness of condensation chemistry to combine LBUs into a series of peptides of 
various lengths. Maximal activity was observed at 24 residues, similar to the average length of 
32 residues observed in naturally occurring AMPs. Because previous experiments had shown 
that tryptophan increases antimicrobial activity of peptides (36; 37; 38), valine residues of the 
LBU were replaced with tryptophan residues, producing a series of WLBU peptides of various 
lengths (35). From this series of peptides, WLBU2 had emerged as our frontrunner peptide based 
on its broad range of activity (Figure 3). WLBU2 forms a helix with a higher hydrophobic 
moment than LL-37 and it forms a more perfectly amphipathic structure, indicating that rational 
design can create AMPs with idealized structural properties.  
7 
WLBU2 has been studied for its antibacterial activity in vitro against a wide range of 
Gram positive and Gram negative bacteria. Antibacterial activity has been observed in sub-
micromolar concentrations for various strains of Pseudomonas and Staphylococcus in various 
salt concentrations, outperforming LL-37 in the same assays to measure minimum bactericidal 
concentration (MBC) and minimum inhibitory concentration (MIC; Table 1) (35; 39). 
Furthermore, WLBU2 has been shown to have activity against other pathogenic bacteria,  
including Burkholderia, Enterococcus, and Acetinobacter, as well as some pan-resistant strains 
(40). Interestingly, WLBU2 retains activity in high salt, serum, and whole blood environments, 
in which LL-37 has little to no detectable activity (39; 41). This indicates that the rational 
engineering of peptides can overcome the natural limitations of host-derived peptides. WLBU2 
Hydrophobic residues are shown in yellow and cationic residues are shown in 
blue. The direction of arrow represents hydrophobic moment (µH), with the length 
of the arrow indicating strength. 
Figure 3. Helical wheel models comparing hydrophobic residue segregation of 
WLBU2 against LL-37.  
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has also displayed antiviral activity in preliminary experiments in vitro and in vivo against a 
variety of mammalian enveloped viruses. Antiviral activity was detected against HIV  
Table 1. MBC and MIC values for P. aeruginosa strain PAO1 and methicillin-resistant  S. 
Aureus (MRSA) in phosphate buffer (PB), PB containing 150 mM NaCl (PBS), and 
Mueller-Hinton broth (MHB). 
PAO1 MRSA 
MBC* (µM) MIC† (µM) MBC* (µM) MIC† (µM) 
PB PBS MHB PB PBS MHB 
WLBU2 0.6 0.6 4 0.6 0.6 2 
LL-37 1.2 1.2 8 1.2 6 >32 
and influenza A. Mice infected with a 70% lethal dose of influenza A strain PR8 were able to 
survive disease when treated with WLBU2 intranasally (results not published). Based on these 
data, WLBU2 can potentially be developed for use as a broadly active antiviral peptide. In 
principle, this is an attractive idea because antiviral treatments currently available are virus-
specific. By increasing peptide specificity for properties of viral envelopes shared among various 
families of viruses, the antiviral activity of WLBU2 could be increased against a variety of 
mammalian enveloped viruses that are significant public health threats. 
*MBC measured as concentration of peptide reducing viable bacteria within a suspension by
three orders of magnitude. 
†MIC measured as concentration reducing bacterial growth by at least 90%. 
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1.3 CRAC MOTIFS 
Specifically targeting viral envelopes is difficult because the phospholipid profiles of 
viral and host cellular lipid membranes are similar. However, studies of viral envelopes have 
identified an increase of the cholesterol-to-phospholipid (C/P) ratio as compared to the host 
membranes from which they are derived. This cholesterol enrichment has also been shown to be 
necessary for virus infectivity (42). An amino acid sequence called the cholesterol recognition 
amino acid consensus sequence (CRAC) motif can direct proteins to cholesterol-rich membranes 
(43), representing a plausible targeting strategy for enveloped virus inactivation. The CRAC 
motif is a flexible sequence of anywhere from 5 to 13 amino acids that directs proteins to 
cholesterol rich regions of membranes. The consensus sequence is L/V – X(1-5) – Y – X(1-5) – 
R/K, in which X(1-5) represents one to five residues of any amino acid (44). This motif is 
thought to function by stably interacting directly with a cholesterol molecule by stacking of 
aromatic groups (43). It appears proper CRAC function relies on structural flexibility of the 
motif to allow for stable and specific interaction with cholesterol (45). There are millions of 
possible CRAC motif sequences, though it is likely that not all lengths and sequences are equally 
efficient. Studies have shown that making single amino acid changes or additions in an 
established CRAC motif sequence can alter cholesterol specificity (45). 
One well studied CRAC motif is LWYIK found in HIV gp41. This is the shortest 
possible CRAC motif, and its activity has been well characterized. Single amino acid mutations 
to the first, third, and fifth residues of LWYIK have shown that these residues are most important 
for efficient interactions with cholesterol (45). This also revealed that drastic changes could be 
made to the rest of the sequence with little to no effect on cholesterol interactions. Other work 
with the LWYIK CRAC motif in the context of HIV gp41 has revealed that this sequence inserts 
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specifically into the cholesterol-enriched viral envelope to encourage destabilization of the 
membrane and to allow for fusion with the host cell (46; 47). These studies indicate that CRAC 
motifs could be designed to follow the appropriate sequence that could interact specifically with 
cholesterol rich membranes.  
1.4 SELECTED MODEL VIRAL MEMBRANES 
For this study, three viruses were selected against which CRAC motif containing peptides 
were tested for their ability to inactivate infection. These viruses, each from different virus 
families, were chosen to represent a spectrum of lipid:protein content and lipid surface exposure 
in the viral envelope. The following viruses also represent significant contributors to global 
morbidity and mortality caused by viral disease. 
1.4.1 Human Immunodeficiency Virus 
HIV is a recently emerged lentivirus that can lead to acquired immune deficiency 
syndrome (AIDS), a disease characterized by impaired immune function leading to fatal 
opportunistic infections. There are currently no vaccines against HIV, though quality of life after 
infection can be maintained for decades through antiretroviral therapies. The World Health 
Organization (WHO) estimated that as of 2012, 35.3 million people were currently infected with 
HIV, with 2.3 million new infections occurring within that year. During this period from its 
discovery in 1983 to 2012, the WHO estimates 36 million people have died of HIV and HIV-
related complications (48). 
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The HIV virion is enclosed in a host-derived lipid envelope surrounding a proteinaceous 
capsid that protects the viral genome (Figure 4a). The virus membrane is studded with about 7 to 
14 copies of the virally-derived envelope (Env) trimer consisting of gp120 and gp41 (49). The 
lipid bilayer has been shown to be derived specifically from detergent-resistant, cholesterol and 
sphingomyelin rich regions of the host cell membrane, sometimes called lipid rafts (50). Studies 
of the composition of the HIV envelope have revealed that the viral membrane has a 
significantly higher cholesterol:lipid ratio than corresponding host cell membranes, with C/P 
ratios ≥ 0.8 in both clinical and laboratory isolates (51), whereas human skin fibroblasts have a 
C/P ratio of about 0.15 in normal growth media conditions (52). Furthermore, the presence of 
cholesterol in the viral envelope has been shown to be necessary for proper fusion, while 
cholesterol depletion significantly reduces infection (53; 54). In the context of testing cholesterol 
targeting AMPs, the HIV virion models a membrane with low protein density and high surface 
lipid exposure. 
12 
 
A. HIV model showing lipid bilayer and approximately 7 Env trimers on the surface of the 
virion. Model is adapted from (105). B. Influenza model showing lipid bilayer studded 
with multiple copies of HA and NA with less surface lipid exposure as compared to the HIV 
model. Model is adapted from (105). C. DENV model showing both a cutaway to the 
interior of the virion as well as a model of the outer surface covered by icosahedral shell of E 
protein. Model is adapted from (106).
Figure 4. Schematic diagra ms of panel of viruses chosen to test CRAC  motif containing  
peptides against.  
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1.4.2 Influenza A Virus 
Influenza A virus is an orthomyxovirus that causes respiratory illness in yearly seasonal 
pandemics. Influenza-associated hospitalizations and mortality most severely impact the elderly 
(65+ years old) and juvenile (<5 years old) age groups (55). For the 2003 United Stated influenza 
season, a moderately severe season, the total economic burden of the epidemic is estimated to 
have cost about $87.1 billion and resulted in 44 million productive days lost due to illness or 
death, representing a significant public health threat to the US (56). The WHO established the 
Global Influenza Surveillance Network (GISN) to monitor global trends of influenza disease, 
allowing for the annual production of influenza vaccines against current circulating strains (57). 
However, influenza A can mutate rapidly within humans, birds, and pigs, leading to emergence 
of new virulent strains of influenza A to which the human population has no natural immunity 
(58). The recent emergence of avian virus H5N1, which has been shown to cause disease in 
humans, provides an ongoing example of the mutagenic potential to create new epidemic strains 
of virus (59). Currently, there are few antiviral therapies against influenza A, though some 
including oseltamivir and zanamivir do exist (60). 
The influenza A virion is a spherical or filamentous particle enclosed in a lipid membrane 
that surrounds eight RNA segments wrapped around and protected by the nucleocapsid protein. 
The viral membrane is studded with three different virally derived proteins: hemagglutinin (HA), 
neuraminidase (NA), and M2 matrix protein (Figure 4b) (61). During assembly, these three 
proteins will assemble specifically in areas of the membrane that are insensitive to detergent 
solubilization, a defining property of lipid rafts (62). The lipid composition of the viral envelope 
matches that of ordered lipid raft domains of mammalian cells and indicates that increased 
cholesterol content of the envelope is necessary for infection. Studies of purified virus particles 
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have determined that 44% of envelope lipid is cholesterol, accounting for about 12% of the total 
virion mass (63). Studies of the surface of the 2009 pandemic H1N1 virus have indicated that 
even though there is a relatively high surface expression of HA and NA proteins, antibodies are 
still able to access the stem regions of HA that are close to the viral membrane, indicating that 
there is accessibility to the lipid envelope (64). In the context of testing cholesterol targeting 
AMPs, the influenza A virion models a membrane with high protein density and moderate 
surface lipid exposure. 
1.4.3 Dengue Virus 
Dengue virus (DENV) is an acute mosquito-borne virus of the Flavivirus family that is 
endemic in tropical and sub-tropical regions of the globe, especially South East Asia and Africa. 
DENV is considered the most important arboviral disease globally by the WHO because 50% of 
the world’s population lives in countries where the disease is endemic (65). Infection causes 
multiple disease outcomes of varying clinical severity: Dengue fever (DF), Dengue hemorrhagic 
fever (DHF), and Dengue shock syndrome (DSS). In the past decade, more countries have 
reported increasing cases of DF or DHF due to issues such as global travel, climate change, and 
breakdown of vector control mechanisms (66). Recent estimates on the number of people 
infected globally per year approximate 390 million new infections with 96 million clinical 
manifestations of disease (67). In most endemic countries, children constitute most of the burden 
of mortality (68). Currently, there are no vaccines or specific antiviral treatments against DENV 
infection. 
The DENV virion is distinct from that described for HIV and influenza A. The DENV 
genome is protected by an inner nucleocapsid protein that is then surrounded by a capsid. This 
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capsid is then surrounded by a host derived lipid membrane. Distinct from both HIV and 
influenza A, the DENV lipid envelope is further protected by an icosahedral shell formed by 90 
copies of the E protein dimers, embedded in the membrane by complexation with the M protein 
(Figure 4c) (69; 70; 71). Similar to HIV and influenza A, recent studies have shown that 
assembly of DENV is dependent on lipid raft regions where depletion of cholesterol from the 
host cell leads to decreased virus production (72). Though there have been no studies to directly 
measure how much cholesterol is present in the DENV envelope, it has been shown that 
depletion of cholesterol from the viral envelope reduces viral infectivity, indicating an essential 
role for cholesterol in the viral membrane (73). Given these observations, the DENV virion 
represents a model where the viral envelope has a very high protein:lipid ratio and very low lipid 
surface exposure.  
 
Based on the observation that many mammalian viral envelopes are enriched for 
cholesterol as compared to host cell membranes, we hypothesized that AMPs could be developed 
as antiviral agents by specifically targeting cholesterol-rich membranes. We hypothesized that 
addition of CRAC motifs to WLBU2 would increase peptide specificity for cholesterol-rich 
membranes intrinsic to enveloped mammalian viruses. These CRAC motif-containing peptides 
would interact with viral envelopes based on the different C/P ratios as compared to the host 
cells, thereby presenting a new strategy of antiviral treatment against a broad range of 
mammalian viruses. We predicted that viral inactivation by CRAC motif containing peptides 
would correlate to lipid surface exposure based on a membrane disruptive mechanism of action. 
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2.0  STATEMENT OF PURPOSE 
Enveloped viruses, including HIV, influenza, and flaviviruses, are a significant cause of 
morbidity and mortality across the globe. There are few effective antiviral therapies that exist 
and those that do are highly pathogen-specific, often developed with the intent to treat one 
specific virus. One problem with this form of treatment is the ability to develop resistance 
mechanisms to the drug. Therefore, there is a critical need to develop novel therapeutics that 
have a broad range of activity and are difficult for resistance to be developed.  
In the past two decades, AMPs have been extensively studied and developed for their use 
as antibacterial agents. While antiviral activity has been examined for some naturally-derived 
peptides, little work has been done to specifically engineer peptides as antiviral agents. The 
engineered cationic antimicrobial peptide WLBU2 developed by our lab has demonstrated in 
preliminary experiments the ability to inactivate enveloped mammalian viruses, through a 
presumed membrane disruptive mechanism. The goal of this work was to determine whether the 
antiviral activity of WLBU2 could be increased by the addition of the CRAC motif in order to 
direct peptides specifically to cholesterol-rich membranes. Because viral envelopes are enriched 
for cholesterol as compared to host mammalian cells, we hypothesized that addition of the 
CRAC motif would direct WLBU2 specifically to viral envelopes, disrupting the membrane and 
therefore inactivating virus and blocking infection. This marks a novel antiviral strategy in which 
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entire classes of viruses can be targeted by a mechanism in which viruses are unknown to be able 
to develop resistance.  
2.1 SPECIFIC AIM 1: TO DESIGN, MODEL, AND CHARACTERIZE CRAC MOTIF 
CONTAINING PEPTIDES. 
Because the CRAC motif is a domain with millions of possible amino acid sequences, 
motifs will be designed for addition to WLBU2. In order to determine the optimal location for 
addition of CRAC motifs to WLBU2, modeling will be carried out to predict the structures of C- 
and N-terminal CRAC motif containing WLBU2 peptides. Once peptides are produced with the 
appropriate CRAC motif additions, peptides will be characterized by circular dichroism (CD) 
spectroscopy in various solvent environments and analyzed for secondary structure composition. 
2.2 SPECIFIC AIM 2: TO EVALUATE ANTIVIRAL ACTIVITY OF THESE 
PEPTIDES AGAINST VARIOUS ENVELOPED VIRUSES IN VITRO. 
CRAC motif containing peptides will be tested for their antiviral activity against the 
following enveloped mammalian viruses: HIV, influenza A, and DENV. This panel of viruses 
was chosen because they represent a range of membrane protein concentrations and lipid surface 
exposures. Peptides will be tested against each virus in the appropriate infection assays to 
measure how pre-treatment of virus with peptide affects infectivity. These measures of 
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inactivation will be compared to WLBU2 alone in order to determine whether addition of the 
CRAC motif enhances antiviral activity. 
2.3 SPECIFIC AIM 3: TO ASSESS CYTOTOXICITY OF CRAC MOTIF 
CONTAINING PEPTIDES AGAINST A PANEL OF TRANSFORMED AND NON-
TRANSFORMED CELLS AND CELL LINES. 
To measure toxicity of peptides against host cells, two cytotoxicity assays will be carried 
out: hemolysis and MTS assays. These two measures of cytotoxicity were chosen because they 
are both established standards of the field and they measure cytotoxicity by different methods. 
The hemolysis assay measures direct lysis of red blood cells (RBCs) while the MTS assay 
measures metabolic activity of cells indicating viability. For the hemolysis assay, RBCs in 
phosphate buffered saline (PBS) will be treated with varying concentrations of each of the 
peptides to measure release of hemoglobin, indicating cell lysis. For the MTS assay, a panel of 
both transformed and non-transformed cells will be tested to determine a range of cytotoxic 
activity of the peptides. Transformed cells were chosen as they are the relevant indicator cells for 
each of the virus inactivation assays performed. A non-transformed cell line and primary cells 
were also chosen because previous research has found that transformed cells are more 
susceptible to peptide treatment than non-transformed cells. Cells will be treated with various 
concentrations of each peptide, and then allowed a short recovery period before carrying out the 
MTS assay for cell viability.  
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3.0  MATERIALS AND METHODS 
3.1 MODELING 
The peptide modeling program PEP-FOLD was used to predict the structure of CRAC 
motif-containing WLBU2 peptides (http://bioserv.rpbs.univ-paris-diderot.fr/PEP-FOLD/). 
Sequences were run on a short simulation and models were sorted by sOPEP, which clusters 
models based on similar energy states based on simplified side chains (74). PEP-FOLD predicts 
peptide conformations based on the amino acid sequence using coarse-grain simulation to look at 
interactions between four amino acids at a time (75). Models generated in PEP-FOLD are sorted 
into clusters based on structural similarity. All models that were analyzed were representative of 
a single model cluster. Models generated from PEP-FOLD were then analyzed using PyMol 
molecular visualization software version 0.99 (http://www.pymol.org/). Similarly, helical wheel 
projections and hydrophobicity predictions were created by HeliQuest 
(http://heliquest.ipmc.cnrs.fr/). Helical wheel projections were created using the α-helix setting 
to analyze the full amino acid sequence. This program then analyzes the physiochemical 
properties of the peptide based on its amino acid sequence and the forced helical conformation. 
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3.2 PEPTIDE SYNTHESIS 
Amino acid sequences of the desired peptides (WLBU2 and CRAC modified versions) 
were produced by the University of Pittsburgh Peptide Synthesis Core of the Genomics and 
Proteomics Core Laboratories following previously reported synthesis and purification 
procedures optimized for WLBU2 production (76). Other stocks of the same peptides were 
produced commercially using similar methods by Genscript (Piscataway, NJ). All peptide 
preparations were purified by HPLC to at least 95% purity. Concentrations of peptide dissolved 
in sterile water were determined by a standard ninhydrin assay as previously reported (76). 
Concentrations were confirmed using spectrophotometric methods by A260/A280 determination 
on a NanoDrop 1000 spectrophotometer (NanoDrop, Wilmington, DE). 
3.3 CIRCULAR DICHROISM SPECTROSCOPY 
Measurements were taken at a 40 µM concentration of each peptide in the following 
solvent environments: deionized water, 6 mM sodium dodecyl sulfate (SDS), 30 mM SDS, and 
30% tetrafluoroethylene (TFE). Circular dichroism (CD) measurements were taken with a Jasco 
spectrometer (Aviv Instruments, Lakewood, NJ) at room temperature with a 1 mm path length 
over 185 nm to 260 nm with machine units as output for five scans per sample. The mean residue 
ellipticities ([ϴ]/1,000 × [(degree × square centimeters)/decimole]) were calculated of the 
averaged five scans using Dichroweb (http://dichroweb.cryst.bbk.ac.uk/) (77). These data were 
analyzed using the CDSSTR method (78; 79; 80) with SP175 as the reference data set (81). The 
CDSSTR method was chosen because it produces the most accurate analysis results and SP175 
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was chosen as the reference data set because it contains the most reference proteins at the 
necessary wavelengths for comparison to the data that was collected with CRAC motif 
containing peptides. 
3.4 CELL PROPAGATION 
The following cell lines were propagated in Dulbecco’s Modified Eagle Medium 
(DMEM; Life Technologies, Grand Island,NY) containing 10% fetal bovine serum (FBS) and 
1% L-glutamine: MDCK, MRC-5, HEK239T/17, VeroE6, and TZM-bl (NIH AIDS Research 
and Reference Reagent Program, Germantown MD) cells. To passage, cells were treated with 
0.05% Trypsin/0.53 mM EDTA in HBSS (Corning, Manassas, VA) for 10-15 minutes before 
transferring a subset of cells to a new flask with fresh complete media. 
3.5 ISOLATION OF HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS 
Human PBMCs were isolated from heparinized human blood from healthy donors (with 
the approval of the University of Pittsburgh Institutional Review Board) as previously described 
(39). Briefly, Histopaque gradient centrifugation was performed at 1000 rpm for 20 min with the 
brake off. PBMCs were collected, washed with PBS at least twice, and suspended in PBS. Cells 
were stored in liquid nitrogen in 10% DMSO, 90% FBS for less than a month before use, with 80 
– 85% viability maintained.  
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3.6 VIRUS STOCK PREPARATION 
3.6.1 HIV 
To produce stocks of HIV, HEK293T/17 cells plated in 6-well plates grown to 90 – 95% 
confluence were transfected with 2.5µg of DNA using Lipofectamine LTX and Plus reagent 
according to the manufacturer’s instructions (Life Technologies, Grand Island NY). Infectious 
HIV-1 89.6 virus was produced by transient transfection of HEK293T/17 cells with the plasmid 
pUC19-89.6 wild type, with media replacement at 4 hours post transfection. Viral supernatant 
was retrieved 48 hours after the transfection and centrifuged at 663xg for 10 min at 4°C.  
3.6.2 Influenza A 
To produce stocks of influenza A, MDCK cells in a 150 cm2 cell culture flask grown to 
about 90% confluence were infected with influenza virus strain PR8 (A/Puerto Rico/8/1934) at 
an MOI of 1. Infected cells were incubated in media containing DMEM, 0.2% Bovine Albumin 
Fraction V (BSA; Life Technologies, Grand Island,NY), and 2 ug/mL TPCK-treated Trypsin 
(Sigma-Aldrich, St. Louis, MO) for 48 hours until CPE was observed and cells were not adhered. 
Just before virus was collected, BSA was added to culture medium to a final concentration of 
0.3%. Cells and culture supernatant were then centrifuged at 600xg for 10 min at 4°C to pellet 
debris. Virus was aliquoted and frozen before titration by plaque assay. 
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3.6.3 DENV 
Stocks of DENV serotype 2 kindly provided by Priscila Castanha of Dr. Ernesto 
Marques’s lab (Center for Vaccine Research, University of Pittsburgh). 
 
3.7 ANTIVIRAL ACTIVITY 
3.7.1 HIV 
To test HIV inactivation, a viral infection neutralization assay was carried out on TZM-bl 
cells in 96-well flat bottom plates to measure production of luciferase under control of the HIV-1 
promoter. Cells were plated at a concentration of 2.5 x 104 cells/well and allowed to adhere at 
37oC/5% CO2 for 7 hours. HIV strain 89.6 was diluted so as to produce about 3 x 104 RLUs/well 
in untreated control wells. Peptide dilutions were prepared in a 96-well U-bottom plate by 2-fold 
serial dilutions starting at 100 µM down to 0.78 µM in DMEM containing 10% FBS. Equal 
volumes of virus stock were added to each well of peptide for a final volume of 40 ul and 
incubated together at 37oC/5% CO2 for 1 hour. Virus-peptide mixtures were then brought up to 
total volume of 200 ul (5 fold dilution) and plated on adhered TZM-bl cells for 1 hour and then 
removed and replaced with fresh complete media. Plates were incubated for 48 hours and then 
cells were lysed with 50µl of cell culture lysis reagent, and luciferase activity was read using the 
luciferase assay system according to the manufacturer’s instructions (Promega, Madison WI) 
using an Orion Microplate Luminometer (Berthold, Oak Ridge TN). 
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3.7.2 Influenza A 
To test influenza A inactivation, a plaque assay was carried out on MDCK cells (82) 
using virus that had been pre-incubated with peptide. Influenza strain PR8 was diluted to a final 
concentration of 160 pfu/ml then mixed with an equal volume of prepared dilutions of peptide. 
Peptide had been diluted by 2-fold serial dilution using DMEM containing 0.2% BSA in 1.5 mL 
Eppendorf tubes starting at 100 µM down to 0.78 µM. Peptide-virus mixtures were incubated at 
37oC/5% CO2 for 1 hour. MDCK cells between passages 3 and 10 plated in 6-well plates at 8 x 
105 cells/well were grown to 90-100% confluence were washed twice with serum-free media 
then exposed to pre-incubated virus-peptide mixtures for 45 minutes in duplicate. Virus and 
peptide were removed and replaced with plaquing media containing DMEM, 10% FBS, 2.5 
ug/mL TPCK-treated Trypsin, and 0.4% agarose. Infected and treated cells were then grown at 
37oC/5% CO2 for 5 days before being stained with 35% EtOH/0.25% Crystal violet overnight at 
4oC. Stain and agarose plugs were removed and plaques were counted by eye using a light box. 
All plaque assay experiments were carried out at least three times. 
3.7.3 DENV 
To test DENV inactivation, a plaque assay was carried out on VeroE6 cells (83) using 
serotype 2 virus that had been pre-incubated with various concentrations of peptide. Virus was 
diluted by 103 fold and mixed with an equal volume of prepared dilutions of peptide. Peptide had 
been diluted by 2-fold serial dilution using MEM containing penicillin/streptomycin, and 
Fungizone (Life Technologies, Grand Island NY) in a 96 well plate starting at 50 µM down to 
1.5625 µM. Peptide-virus mixtures were incubated at 37oC/5% CO2 for 1 hour. VeroE6 cells 
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between passages 25 and 42 plated in 24-well plates at 1.5 x 105 cells/well 48 hrs in advance 
were grown to 90-100% confluence were then exposed to pre-incubated virus-peptide mixtures 
for 1 hr in duplicate. Virus and peptide were removed and replaced with semi-solid media 
containing 3% carboxymethylcellulose (CMC), MEM, 10% FBS, penicillin/streptomycin, and 
Fungizone. Infected and treated cells were then grown at 37oC/5% CO2 for 6 days before fixing 
and staining. Semi-solid medium was removed from cells before addition of formalin and cells 
were then allowed to incubate at room temperature for 1 hr. Formalin was removed, the cells 
were washed, and then crystal violet was added. Plates were incubated for 1 hr at room 
temperature and washed again before plaques were counted. All experiments were carried out at 
least three times.  
3.8 CYTOTOXICITY 
3.8.1 Red Blood Cell Lysis Assay 
A modified version of the RBC lysis assay carried out by Deslouches et al. (39) was 
performed using RBCs collected during isolation of PBMCs. Erythrocytes were pelleted by 
centrifugation at 1000 rpm for 10 min then diluted to a 10% solution (1:10 dilution) in sterile 
phosphate buffered saline (PBS). Peptide dilutions were created in tissue culture-treated round 
bottom 96 well plates in duplicate ranging in concentration from 100 µM to 0.78 µM. Peptides 
were incubated at 37oC/5% CO2 for 1 hour before an equal volume of 10% RBCs were added to 
each well (1:2) dilution. To produce a standard curve for analysis, 0 to 50 μl of 5% RBC solution 
(1:20 dilution) was added to dH2O to a final volume of 500 μl (up to 1:10 dilution) and incubated 
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for 1 hour along with peptide-RBC mixtures at 37oC/5% CO2. These hemoglobin suspensions 
were then centrifuged at 600xg for 10 min to pellet intact RBCs. In a 96 well flat bottom plate, 
20 ul of supernatant from each peptide-RBC mixture was diluted 10-fold in 180 ul of sterile 
dH2O. Absorbance readings were taken at 570nm on a SpectraMax 340PC384 Absorbance 
Microplate Reader (Molecular Devices, Sunnyvale, CA). 
3.8.2 MTS Assay 
Cytotoxicity measurements were taken on selected transformed and non-transformed 
cells using a tetrazolium-based colorimetric MTS assay, a one-step variation of the classic MTT 
assay (84). The MTS assay measures cell viability by detecting metabolically active cells that 
reduce MTS to a colored formazan reagent. Cells were plated in 96-well plates and allowed to 
grow to 90 – 100% confluence. Peptides starting at 50 µM were diluted by serial two-fold in a 96 
well U-bottom plate and incubated at 37oC/5% CO2 for 1 hour. Cells were then treated with each 
concentration of peptides for 1 hour, at which time the peptide-containing supernatant was 
removed and replaced with fresh complete media. Cells were then allowed to recover at 37oC/5% 
CO2 for 4 hours before performing an MTS assay. This assay was carried out using the CellTiter 
96 AQueous One Solution Cell Proliferation Assay following the manufacturer’s protocol 
(Promega, Madison, WI). Briefly, MTS reagent was added to cells, and then incubated at 
37oC/5% CO2 for 2 hours before spectrophotometric readings were taken at 490nm on a 
SpectraMax 340PC384 Absorbance Microplate Reader (Molecular Devices, Sunnyvale, CA).  
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4.0  RESULTS 
4.1 DESIGN 
4.1.1 CRAC Motif Design 
Following the characteristic sequence (L/V – X(1-5) – Y – X(1-5) – K/R), CRAC motifs 
were designed for addition to WLBU2 to increase cholesterol specificity. Initially, addition of 
LWYIK from the HIV fusion protein gp41 was selected for evaluation because it is well-
characterized (45; 46; 47) and would give us a basis of comparison for how a completely 
synthetically designed CRAC motif may function. In order to develop a CRAC motif with 
minimal amino acid differences from the sequence of WLBU2, a synthetically designed CRAC 
motif was created. The CRAC motif VWYVK was designed that follows the characteristic 
CRAC sequence as described above. This sequence is the shortest possible CRAC motif and 
minimizes differences between the WLBU2 amino acid sequence by only introducing two new 
amino acids, as opposed to four different amino acids found in LWYIK. By minimizing the 
number of unique amino acids in a sequence, the cost of production of peptides is reduced. While 
the CRAC sequence indicates it is possible to have an arginine in the last position, further 
minimizing amino acid differences, there is evidence that, in the case of the LWYIK motif, the 
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terminal lysine is important for maintaining structural flexibility of the peptide (43). For this 
reason, lysine was retained in the last amino acid position. 
4.1.2 Predictive Modeling 
Modeling was carried out in order to examine the predicted effect of CRAC motif 
contributions on WLBU2 structure and to determine the optimal location for this modification in 
the peptide sequence. These structural modeling studies employed PEP-FOLD modeling 
software, which has been optimized to predict secondary structure of short amino acid sequences 
based on a coarse grain, multiple simulation analysis using a structural alphabet for reference 
(75). In the models produced, we hoped to see that addition of the CRAC motif would not 
disrupt the predicted structure of WLBU2 and that the terminal CRAC motif would remain 
unstructured, thus maintaining the flexibility necessary for CRAC function (45). Each CRAC 
motif, LWYIK and VWYVK, was added to either the C- or N-terminus of WLBU2 and modeled 
using PEP-FOLD. PEP-FOLD sorts models into clusters that are ranked based on sOPEP scores. 
As described in Materials and Methods, sOPEP can score the models generated based on the 
energetic landscape of peptides with simplified side chains (74). Peptides with similar sOPEP 
scores are grouped together into clusters characterized by a single representative model. In C-
terminal modeling, PEP-FOLD predicted 172 models sorted into five clusters for LWYIK and 
190 models sorted into 8 clusters for VWYVK. For both motifs, a single model cluster each 
represented at least 95% of all the models generated (Figure 5a). These two largely 
representative models were then aligned to WLBU2 (Figure 5b). In all models generated, there 
was no predicted direct interaction between the CRAC motifs and WLBU2 peptide sequence. 
However, according to modeling predictions, addition of the CRAC motif to the C terminus of 
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WLBU2 would have a largely helical structure maintained throughout the peptide, including the 
C-terminal CRAC motif. Because the C-terminal CRAC motif is helical, there is not the 
flexibility necessary for proper CRAC motif function. 
In adding the CRAC motifs to the N-terminus of WLBU2, PEP-FOLD predicted 190 
models sorted into 20 model clusters for LWYIK and 175 models sorted into 19 model clusters 
for VWYVK. None of the predicted models indicated any interaction between CRAC motifs and 
WLBU2 peptide sequence. Clusters containing the most models were selected for further 
analysis as they appeared to have lower sOPEP scores, indicating a more favorable energetic 
conformation. We found that for N-terminal LWYIK, three model clusters (3, 6, and 9) 
represented approximately 80% of all the models generated, while three model clusters of N-
terminal VWYVK (1, 3, and 11) represented about 85% of all the models generated (Figure 6a). 
A. The most representative model clusters of WLBU2 containing each CRAC motif are shown 
on the left with cluser distributions shown on the right, where the colors of the models on the left 
correlate to the cluster distribution on the right. The models shown represent 95% of all models 
produced by PEP-FOLD. B. Alignment of models displayed in A with WLBU2. CRAC motif 
residues are represented by stick model to highlight the α-helical structure formed by the motif.
Figure 5. PEP-FOLD modeling predictions for WLBU2 peptides containing C-terminal 
CRAC motifs. 
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The largest cluster (3 for LWYIK and 11 for VWYVK) of these representative three were 
aligned to WLBU2 (Figure 6b). According to modeling predictions, addition of the CRAC motif 
to the N terminus of WLBU2 would produce a largely helical peptide with an unstructured N-
terminal CRAC motif. 
Based on the modeling predictions, four peptides containing each CRAC motif on the N-
terminus either once or twice (as listed in Table 2) were selected for production by solid phase 
peptide synthesis (76). Peptides were produced with the CRAC motif added to the N-terminus 
twice to investigate whether addition of multiple CRAC motifs affects peptide activity or 
cholesterol specificity. Peptides containing two CRAC motifs were not modeled because at 34 
residues long, PEP-FOLD software is less accurate in predicting secondary structure (75). 
 
A. The most representative model clusters of WLBU2 containing each CRAC motif are 
shown on the left with cluster distributions shown on the right, where the colors of the models 
on the left correlate to the cluster distributions on the right. The models shown represent 80 - 
85% of all models produced by PEP-FOLD. B. Alignment of a single model cluster 
displayed in A (LWYIK – green, cluster 9; VWYVK – aubergine, cluster 11) with 
unmodified WLBU2. CRAC motif residues are represented by stick model to highlight the 
predicted flexibility of the motif.
Figure 6. PEP-FOLD modeling predictions for WLBU2 peptides containing N-terminal 
CRAC motifs.  
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Table 2. CRAC Motif Containing Peptides. 
Peptide Length Molecu-
lar 
Weight 
(g/mol) 
Sequence 
LWYIK 29 4104.04 LWYIKRRWVRRVRRWVRRVVRVVRRWVRR 
LWYIK2 34 4807.93 LWYIKLWYIKRRWVRRVRRWVRRVVRVVRRWVRR 
VWYVK 29 4075.99 VWYVKRRWVRRVRRWVRRVVRVVRRWVRR 
VWYVK2 34 4751.82 VWYVKVWYVKRRWVRRVRRWVRRVVRVVRRWVRR 
 
4.2 SECONDARY STRUCTURE CHARACTERIZATION 
Once peptides had been produced, structural characterization was carried out by CD 
spectroscopy in the following solvent environments: dH2O, 6 mM SDS, 30 mM SDS, and 30% 
TFE. TFE is a hydrophobic solvent that would mimic the hydrophobic core of a lipid bilayer, 
whereas SDS forms micelles acting as an approximate membrane mimic. SDS forms micelles at 
concentrations of 30% or greater at room temperature (85); micelles mimic the hydrophobic-
aqueous interface that would be encountered at the surface of a lipid bilayer. Previous studies 
analyzing WLBU2 by CD spectroscopy indicated that WLBU2 assumes a predominantly random 
coil conformation with no appreciable structure in phosphate buffer (PB) which mimics an 
aqueous environment, whereas in 30% TFE, WLBU2 forms a distinct α-helix with 
approximately 81% helical content (35). For this study, mean residual ellipticity (MRE) values 
were calculated from machine units using the Dichroweb program and plotted versus 
wavelength. Predicted structural content for all peptides in each solvent environment is 
summarized in Table 3.  
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Table 3. Secondary structural content of CRAC motif containing peptides based on CD 
analysis using CDSSTR method on Dichroweb. 
 dH2O 6 mM SDS 30 mM SDS 30% TFE 
Peptide α-Helix Random 
Coil 
α-Helix Random 
Coil 
α-Helix Random 
Coil 
α-Helix Random 
Coil 
LWYIK 55% 21% 85% 5% 88% 3% 78% 9% 
LWYIK2 55% 21% 85% 4% 87% 4% 79% 6% 
VWYVK 52% 23% 91% 2% 85% 3% 78% 9% 
VWYVK2 56% 24% 88% 5% 82% 5% 76% 10% 
 
 
For each of the CRAC motif containing peptides in dH2O, MRE curves were typical of a 
random coil indicating that in water the peptides are in a random coil conformation with about 
50% helical content (Figure 7a). In both 6 mM and 30 mM SDS, MRE curves revealed 
pronounced minima at 208 nm and 222 nm that are characteristic of peptides that are mostly α-
helical in content (Figure 7b, c). In complexes with SDS, all CRAC motif containing peptides 
contained >80% helical character. Similar MRE curves were found when peptides were analyzed 
in the presence of 30% TFE (Figure 7d). In 30% TFE, all peptides were found to contain about 
75% helicity. Based on CD spectroscopy, all of the CRAC motif containing peptides form 
similar structures to each other in each solvent environment and appear to characterize similarly 
to WLBU2 when compared to previously reported experiments. These findings are consistent 
with the modeling predictions showing that CRAC motif containing peptides maintain helical 
content. 
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4.3 ANTIVIRAL ACTIVITY 
4.3.1 HIV 
In order to determine antiviral activity of the various CRAC-modified peptides against 
HIV in vitro, viral inactivation was assessed by a luciferase-based infectivity assay system on 
  
MRE ([ϴ]/1,000 × [(degree × square centimeters)/decimole]) is plotted against wavelength. 
A. CD spectra in aqueous solvent - dH2O. B. CD spectra in membrane mimic solvent - 6 
mM SDS. C. CD Spectra in membrane mimic solvent - 30 mM SDS. D. CD spectra in 
hydrophobic solvent - 30% TFE.
Figure 7. CD spectroscopy results of CRAC motif containing peptides in various 
solvent environments.  
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TZM-bl cells. HIV strain 89.6 was pretreated with varying concentrations of each of the peptides 
before exposure to TZM-bl cells. Percent inactivation was calculated based on comparison of 
luciferase production to untreated controls. For each of the peptides tested, viral inactivation was 
observed at the highest concentrations tested, 50 and 25 µM. However, at concentrations below 
25 µM, all of the CRAC motif containing peptides showed enhancement of viral infection 
(Figure 8). This enhancement was greater than that observed for WLBU2, where WLBU2 still 
showed approximately 13% inactivation at 6.25 µM. At 6.25 µM, LWYIK and VWYVK2 
enhanced infection by about 200% over untreated controls, whereas LWYIK2 and VWYVK 
enhanced infection by about 100% over untreated controls. While unmodified WLBU2 displayed 
enhancement of infection at concentrations below 6.25 µM, the effect was not as pronounced as 
with CRAC motif containing peptides.  
HIV-1 strain 89.6 was exposed to peptides serially diluted 
two-fold from 50 µM to 0.39 µM for 1 hr before exposure 
to TZM-bl cells. Infection was measured by detection of 
luciferase expression from the HIV-1 promoter. All 
peptides enhance infection at concentrations less than 12.5 
µM, with greater enhancement observed for CRAC motif 
containing peptides. Experiments were repeated twice.
Figure 8. Percent inactivatin of HIV-1.
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4.3.2 Influenza A 
In order to determine antiviral activity of the CRAC-modified peptides against influenza 
virus in vitro¸ inactivation was assessed by a standard plaque assay (82). Influenza A H1N1 
strain PR8 was pretreated with varying concentrations of each of the peptides before exposure to 
MDCK cells. Percent plaque reduction was calculated based on comparison to untreated 
controls. All of the CRAC motif containing-peptides have similar activity against influenza as 
unmodified WLBU2 at concentrations lower than 6.25 µM (Figure 9). At concentrations greater 
than 6.25 µM, all peptides reduced plaques by about 90 - 100%. The data suggests that peptides 
that contain two CRAC motifs have enhanced antiviral activity as compared to corresponding 
peptides with only one CRAC motif. From these data, EC50 values were calculated for each of 
the peptides tested, as summarized in Table 4.  The most active peptide LWYIK2 has at least 
twice the antiviral activity as WLBU2 with an EC50 value as low as 1.33 µM. Even at nanomolar 
concentrations, peptides with two CRAC motifs still retained antiviral activity. At 0.39 µM, 
LWYIK2 reduced plaques by about 31% while VWYVK2 reduced plaques by 37%, whereas at 
the same concentration WLBU2 has no activity against influenza A.  These data indicate that 
pretreatment with CRAC motif-containing peptides enhances influenza virus inactivation as 
compared to WLBU2, with greatest activity displayed when two CRAC motifs are present. 
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Table 4. Calculated EC50 of peptides against influenza 
 A strain PR8. 
Peptide EC50 (µM) 
WLBU2 4.11± 1.08 
LWYIK 4.23 ± 1.11 
LWYIK2 1.33 ± 2.94 
VWYVK 2.40 ± 1.56 
VWYVK2 3.89 ± 1.15 
Influenza strain PR8 was exposed to peptides 
serially diluted two fold from 50 µM to 0.39 µM for 1 
hr before exposure on MDCK cells. Percent plaque 
reduction was measured by comparison to untreated 
controls. CRAC motif containing peptides and 
unmodified WLBU2 display similar levels of 
antiviral activity. Experiments were repeated twice. 
Figure 9. Percent plaque reduction of influenza A.
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4.3.3 DENV 
In order to determine antiviral activity of CRAC modified peptides against DENV in 
vitro  ¸ inactivation was assessed by a standard plaque assay (83). DENV serotype 2 was 
pretreated with varying concentrations of each of the test peptides before exposure to VeroE6 
cells. Percent plaque reduction was calculated based on comparison to untreated controls. All of 
the test peptides inactivated DENV, and CRAC motif containing peptides outperformed 
unmodified WLBU2 alone (Figure 10). All of the CRAC motif containing peptides displayed 
almost 100% plaque reduction at concentrations as low as 1.56 µM. Even at 0.39 µM, the lowest 
concentration tested, CRAC motif containing peptides all displayed antiviral activity against 
DENV serotype 2 was exposed to peptides serially 
diluted two fold from 50 µM to 0.39 µM for 1 hr 
before exposure on VeroE6 cells. Percent plaque 
reduction was measured by comparison to untreated 
controls. CRAC motif containing peptides LWYIK 
(cyan), LWYIK2 (blue), and VWYVK2 (red) were 
about 10-fold more antiviral than unmodified 
WLBU2. Experiments were repeated twice. 
Figure 10. Percent plaque reduction of DENV. 
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DENV. At this concentration, WLBU2 reduced plaques by 16%, as compared to the most active 
peptide VWYVK2, which reduced plaques by 77%. Similarly, at 0.39 µM LWYIK and 
LWYIK2 reduced plaques by 59% and 52%, respectively. From these data, EC50 values were 
calculated for each of the peptides tested, as summarized in Table 5. EC50 values of LWYIK, 
LWYIK2, and VWYVK2 are about 10-fold lower than that of WLBU2 alone with 50% 
reduction of plaques observed at sub-micromolar concentrations. Taken together these data 
indicate that WLBU2 and CRAC motif containing peptides all inactivate DENV serotype 2 in a 
pretreatment assay. 
Table 5. Calculated EC50 of peptides against DENV serotype 2. 
Peptide EC50 (µM) 
WLBU2 3.32 ± 0.64 
LWYIK 0.340 ± 0.049 
LWYIK2 0.366 ± 0.077 
VWYVK 0.635 ± 0.053 
VWYVK2 0.165 ± 0.055 
4.4 CYTOTOXICITY 
4.4.1 Hemolytic Activity 
To investigate the lytic effect of CRAC motif containing peptides against isolates of 
human RBCs, a hemolysis assay was carried out using a standard curve of water-treated RBCs 
39 
for comparison (39). All RBCs were isolated by histopaque gradient centrifugation and 
resuspended in PBS containing no serum. This experiment was carried out individually three 
times with WLBU2 and each of the CRAC motif containing peptides using RBCs isolated from 
independent donors. As shown in Figure 11, the assays revealed very similar patterns of 
hemolysis among the different donor RBCs. In general, the CRAC motif containing peptides had 
greater hemolytic activity than unmodified WLBU. All CRAC motif containing peptides caused 
hemolysis of 50% of RBCs at concentrations less than 20 µM as summarized in Table 6. 
Unmodified WLBU2 displayed 50% hemolysis at a concentration approximately three times that 
as observed for CRAC motif containing peptides, indicating that addition of CRAC motifs 
enhances hemolytic activity of peptides. These data also indicate that peptides containing the 
CRAC motif LWYIK are about 2-fold more hemolytic than peptides that contain the VWYVK 
RBCs isolated from three independent donors were 
exposed to peptides two fold serially diluted from 50 µM to 
0.39 µM for 1 hr. Hemolysis was measured by 
spectrophotometric analysis at 570 nm. CRAC motif 
containing peptides are all more hemolytic than 
unmodified WLBU2.
Figure 11. Percent hemolysis observed after peptide 
treatment. 
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motif. Furthermore, LWYIK2 is a more potent inducer of RBC lysis than LWYIK. On the other 
hand, VWYVK2 is less hemolytic than VWYVK. For all CRAC motif containing peptides, less 
than10% hemolysis was observed at concentrations less than 0.78 µM. These data indicate that 
all CRAC motif containing peptides are more hemolytic than unmodified WLBU2, with 50%  
 
 
Table 6. Calculated 50% hemolysis values of RBCs treated with peptides. 
Peptide 50% hemolysis (µM) 
WLBU2 40.16 ± 7.92 
LWYIK 8.93 ± 2.25 
LWYIK2 5.11 ± 0.92 
VWYVK 10.50 ± 1.38 
VWYVK2 17.98 ± 1.02 
 
 
 
hemolysis values varying based on CRAC motif sequence. Despite the increase in cytotoxicity, 
the concentrations at which CRAC motif containing peptides induce 50% hemolysis are still 
greater than the concentrations at which 50% virus inactivation is observed for both influenza A 
and DENV, indicating that therapeutic levels of peptides are much lower than those at which 
hemolysis occurs. For all of the peptides, EC50 values against DENV are at least 12 fold lower 
than 50% hemolytic values, and in the case of VWYVK2, the EC50 value is over 100 fold lower 
than the 50% hemolytic concentration. 
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4.4.2 MTS Assay 
MTS assays were carried out on a panel of transformed and non-transformed cells to 
assay the effects of peptide treatment on cell viability. The MTS assay measures the amount of 
MTS that is reduced to a colored formazan product by metabolically active cells as a measure of 
viability (86). Cells were treated with various concentrations of each peptide, and then allowed a 
four hour recovery period in fresh complete media before cell viability measurements were 
taken. A four hour recovery period was chosen to allow cells a chance to respond to peptide 
treatment without allowing measurable cell growth over baseline before treatment. Two 
transformed cell lines, TZM-bl and MDCK cells, were chosen to be analyzed as they are the 
relevant indicator cells used for the HIV and influenza A viral inactivation assays, respectively. 
The human fetal foreskin fibroblast cell line, MRC-5, was chosen because the cells are non-
transformed (87) and had been considered in the past for use in production of influenza vaccines 
(88). PBMCs were tested because they are non-transformed, primary cells that WLBU2 had 
previously been tested against in a similar MTT assay (39). Both transformed and non-
transformed cells were tested for cytotoxicity because previous studies have shown that some 
AMPs are more cytotoxic on transformed cells than on primary or non-transformed cells (89; 90; 
91). 
Figure 12 shows viability of the various cells treated with concentrations of each of the 
peptides ranging from 50 µM to 0.39 µM. The cytotoxicity levels are expressed as a percentage 
of cell viability compared to untreated controls. Table 7 lists 50% cytotoxic concentrations 
(CC50), defined as the concentration at which there is a 50% reduction in cell viability as 
compared to an untreated control, for each of the peptides against each of the cells tested. For all 
the cells tested, CRAC motif containing peptides displayed similar cytotoxicity to WLBU2. For  
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Figure 12. Cell cytoxocity as measured by MTS assay. 
Cells were exposed to two fold serially diluted peptide ranging in concentration from 50 µM to 
0.39 µM for 1 hr. Peptides were removed and cells were allowed to recover in fresh complete 
media for 4 hrs before remaining cell viability was read by MTS assay. Top row shows peptide 
cytotoxicity on transformed cell lines TZM-bl (A.) and MDCK (B.), the relevant indicator cells 
for HIV and influenza A infectivity assays, respectively. Bottom row shows peptide cytotoxicity 
on non-transformed cells MRC-5 cells (C.) and PBMCs (D.) Experiments were repeated three 
times. 
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the cell lines tested (TZM-bl, MDCK, and MRC-5), there is little to no difference in cytotoxicity 
observed on transformed versus non-transformed cell lines. CC50 values against each of the cell 
lines tested are significantly higher than the EC50 values calculated against influenza A and 
DENV, indicating that therapeutic levels of peptides are much lower than concentrations at 
which these peptides are causing cytotoxicity. For all of the peptides tested, CC50 values were 10 
to 30-fold higher than the EC50 values against influenza A, and as great as 200-fold higher than 
the EC50 values against DENV. 
 
 
Table 7. Calculated CC50 values (µM) from MTS assay for each of the peptides against all 
of the cells tested. 
 TRANSFORMED NON-TRANSFORMED 
Peptide TZM-bl MDCK MRC-5 PBMC 
WLBU2 30.64 ± 4.89 39.58 ± 8.36 31.21 ± 6.70 8.96 ± 0.79 
LWYIK 21.14 ± 2.65 43.53 ± 4.72 21.93 ± 3.51 10.25 ± 3.72 
LWYIK2 20.65 ± 3.70 29.09 ± 4.20 26.53 ± 4.55 10.95 ± 1.38 
VWYVK 23.25 ± 2.97 31.19 ± 2.90 32.43 ± 3.57 11.24 ± 1.72 
VWYVK2 22.01 ± 2.25 33.85 ± 4.97 36.53 ± 6.46 N/A 
 
 
 
 
Primary, non-transformed PBMCs were isolated from individual donors and stored in 
liquid nitrogen. Cell stocks were then thawed and resuspended in serum-containing media before 
each MTS assay was performed. PBMCs were the most susceptible to peptide treatment of all of 
the cells tested with CC50 values three fold lower than that observed on the cell lines tested. 
Additionally, WLBU2 appeared to be more cytotoxic than CRAC motif containing peptides. For 
the peptide VWYVK2, data were omitted at the highest concentration tested due to issues with 
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solubility. Spectrophotometric readings taken for VWYVK2 at 50 µM and 25 µM showed 
greater absorbance values due to insolubility of the peptide at those concentrations. Higher 
absorbance values indicate greater cell viability in the MTS assay, whereas for VWYVK2 
greater absorbance values were likely a factor of peptide solubility. For all other peptides, at the 
highest concentrations tested, peptides were soluble and the spectrophotometric readings were 
consistent with cell viability readings on the other cell lines tested by MTS assay, where cells 
treated with higher concentrations of peptides displayed less cell viability. 
Selective indices were calculated using CC50 values obtained from MDCK cells and EC50 
values that were reported above for influenza A and DENV. These values are listed in Table 8.  
 
 
Table 8. Selective indices of peptides comparing CC50 of MDCK cells to EC50 against 
influenza A and DENV. 
Peptide Influenza A DENV 
WLBU2 7.45 9.23 
LWYIK 5.00 62.2 
LWYIK2 15.5 56.4 
VWYVK 9.69 36.6 
VWYVK2 5.66 133 
 
 
For influenza A, selective indices for WLBU2 and most CRAC motif containing peptides were 
similar with values ranging from 5 to 9. In the case of LWYIK2, the selective index was 2-fold 
higher than the selective index for unmodified WLBU2 indicating that the peptide has similar 
cytotoxic affect, with greater antiviral activity. For DENV, selective indices of CRAC motif 
containing peptides were 3- to 15-fold higher than that of unmodified WLBU2. For the peptide 
VWYVK2, the selective index with 133 indicating that the concentration at which peptide causes 
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cytotoxicity is 133 times the concentration at which peptide displays antiviral activity. The 
selective indices for DENV indicate that CRAC motif containing peptides have greater antiviral 
activity than unmodified WLBU2. 
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5.0  DISCUSSION 
While AMPs have been extensively explored for their potential as antibiotic alternatives, 
little work has been done to design peptides to specifically enhance antiviral properties. To date 
there is only a limited number of antiviral drug treatments available and these are always virus 
specific. The use of membrane-disruptive peptides as antiviral therapy is an attractive goal 
because treatment could be used against a variety of viral diseases that affect populations 
globally. Preliminary observations using the engineered AMP WLBU2 indicated antiviral 
activity against multiple enveloped viruses suggesting its potential as a broad spectrum antiviral 
treatment.  However, viral envelope lipids lack the high concentration of negative charge that is 
the basis of AMP interaction with and inactivation of bacterial membranes. While viral 
envelopes are not highly negatively charged, mammalian viral envelopes do contain relatively 
high levels of cholesterol compared to their target cells, presumably due to virus budding at 
cellular lipid rafts.  Thus, we hypothesized that the addition of CRAC motifs to WLBU2 could 
substantially increase binding to viral envelope lipids and increase viral inactivation. The current 
studies demonstrate that the addition of CRAC motifs to the N-terminus of WLBU2 yielded only 
a modest 2-fold increase in antiviral activity of WLBU2 against influenza A , with about a 10-
fold increase in antiviral activity against DENV.   This increase in antiviral activity was 
accompanied by a 3-fold increase in the levels of hemolysis and no change in cell viability as 
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compared to unmodified WLBU2 as measured by MTS assay in vitro, the therapeutic index of 
WLBU2 and CRAC-modified derivatives remained similar. 
Initial modeling studies were carried out to predict how addition of a CRAC motif to 
WLBU2 could affect secondary structure. PEP-FOLD modeling predictions indicated that 
addition of the CRAC motif to the N-terminus of WLBU2 would be preferred over C-terminal 
addition because the CRAC motif had no predicted structure, and the main helix of WLBU2 was 
mostly undisturbed. Peptides produced by solid phase peptide synthesis were characterized by 
CD spectroscopy. In agreement with PEP-FOLD modeling predictions, CRAC motif containing 
peptides had >70% helicity and ≤10% random coil in hydrophobic environments (SDS and TFE) 
according to secondary structure analysis using CD data. Furthermore, in dH2O, peptides 
contained about 5-fold more random coil structure. Based on previously reported data, the 
secondary structures of N-terminal CRAC motif containing WLBU2 peptides does not appear to 
differ significantly from WLBU2 alone in the same solvent environments. This suggests that 
addition of the CRAC motif does not disrupt the secondary structure previously observed with 
WLBU2. These data also suggest that PEP-FOLD modeling predictions based on lowest energy 
conformations agree with empirical secondary structure characterizations of peptides in 
hydrophobic environments. 
CRAC motif containing peptides were tested against a panel of viruses representing 
different envelopes with diverse lipid to envelope protein compositions. Viruses were selected 
based on the protein content found on the envelope surface. All of the viruses tested, HIV, 
influenza A, and DENV, have membranes that are enriched for cholesterol. Other studies have 
shown that for each of these viruses, cholesterol is necessary for proper infection as without the 
incorporation of cholesterol there is impaired infection. The viral envelope of HIV contains only 
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about 20 trimers of envelope protein resulting in a very low protein-to-lipid ratio and high 
exposure of lipid at the surface of the virion. Influenza A has an intermediate protein-to-lipid 
ratio with a more dense membrane surface covering of HA and NA proteins. DENV has a very 
high protein-to-lipid ratio, with an outer proteinaceous layer covering the membrane, allowing 
very little surface lipid exposure. Based on these properties, this panel of viruses represents a 
gradient of membrane protein content and lipid surface exposure to test the range of antiviral 
activity of peptides. This panel of reference viruses allowed us to assess the effects of lipid 
exposure on peptide efficacy. 
Unexpectedly, WLBU2 and the CRAC motif containing peptides all displayed 
enhancement of HIV infection in a pretreatment assay. We found that CRAC motif containing 
peptides were greater enhancers of infection than WLBU2 alone, showing up to a 200% increase 
in infection for the cases of LWYIK and VWYVK2. For CRAC motif containing peptides, this 
enhancement effect was observed at concentrations less than or equal to 12.5 µM. WLBU2 alone 
displayed enhancement of infection at concentrations less than or equal to 3.1 µM, with less of 
an increase of infection observed than for any of the CRAC motif containing peptides. For all of 
the peptides, inactivation of HIV was only observed at concentrations greater than 12.5 µM  for 
each of the peptides tested. However, because these peptides show greater cytotoxicity at these 
concentrations, it is likely that what is observed as inactivation could be caused by toxic effects 
of the peptides directly on the cells.   
These results were surprising because the surface of the HIV virion is sparsely populated 
by Env proteins with a high lipid surface exposure.  We hypothesized that this high level of lipid 
surface exposure would make viruses more susceptible to antiviral treatment as peptides would 
readily be able to access the membrane for disruption, leading to inactivation. In contrast to this 
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prediction, peptide treatment of HIV led to enhancement of infection.  The mechanism leading to 
this enhancement phenomenon is uncertain. HIV infection is more efficient when the viral 
envelope has a greater fluidity (92). Peptide interactions with the viral envelope may not disrupt 
the membrane fully, but perhaps increase the fluidity enough to enhance the efficiency of 
infection. CRAC motif containing peptides would enhance infection more as they would be 
expected to interact more readily with the cholesterol-rich viral envelope than WLBU2 alone. 
Another possible hypothesis for this enhancement effect is based on previous observations of a 
semen protein called semen-derived enhancer of viral infection (SEVI) (93). It has been shown 
that the cationic properties of SEVI alone are enough to act as a polycationic bridge to neutralize 
repulsion effects between a negatively charged virion and a target cell (94). Because WLBU2 
and the CRAC motif containing peptides are highly cationic, it’s possible that we are observing a 
similar effect in which these AMPs enhance HIV infection by increasing interactions between 
virions and target cells. In this model, CRAC motif containing peptides are better enhancers of 
infection because they are slightly more negative increasing the interaction between peptides and 
virus, while the overall highly cationic charge of the peptides could create the polycationic 
bridges proposed to enhance infection.  
In marked contrast to HIV, WLBU2 and all of the CRAC motif containing peptides 
inactivated influenza virus in vitro with EC50 values of about 1 – 4 µM. All of the CRAC motif 
containing peptides showed similar activity to unmodified WLBU2 with EC50 values less than 
approximately 4 µM. CRAC motif containing peptides were marginally better at inactivating 
influenza A, whereas the peptide LWYIK2 was the most active with an EC50 value of 1.33 µM. It 
is unclear from this data whether LWYIK or VWYVK confers greater cholesterol specificity, or 
whether the addition of two CRAC motifs enhances this specificity. Cytotoxicity is an issue with 
  50 
this experiment as well because significant reduction in cell viability was observed at 
concentrations greater than or equal to 25 µM. At the highest concentrations tested, it is unclear 
whether the peptide is blocking infection or killing cells that would become infected with live 
and active virus. Despite this concern, based on the MTS assay, there was no observable 
cytotoxicity on cells at concentrations less than or equal to 12.5 µM, while at this same 
concentration at least 75% viral inactivation was observed for all of the peptides. Furthermore, 
the therapeutic index between the EC50 and CC50 values is similar between the CRAC motif 
containing peptides and unmodified WLBU2. These data suggest that therapeutic concentrations 
of peptide are much less than the concentrations required to cause significant cytotoxic effect. 
Further studies on the mechanism of action of these peptides are required, such as flow 
cytometry experiments that analyze infection and cell apoptotic state concurrently after peptide 
exposure.  
Based on the levels of surface exposure of envelope lipids, we predicted that DENV 
would be the least sensitive to inactivation by WLBU2 and its CRAC-modified derivatives. 
Contrary to this hypothesis, we observed that DENV was the most sensitive to inactivation by 
the engineered antimicrobial peptides. This observation suggests that there may be other 
mechanisms of virus inactivation in addition to lipid disruption. One possible mechanism of 
action is by peptide blocking cell surface receptors. The cellular receptors of influenza A and 
DENV, sialic acid (95) and heparan sulfate (96), respectively, are both negatively charged 
molecules found on the cell surface. Because these peptides are highly cationic, introduction of 
these  peptides during infection may block viral entry by peptide binding to cell surface 
receptors, blocking interactions between viruses and their necessary receptors. Further studies on 
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the mechanism of action are required, including confocal microscopy studies using fluorescently 
tagged peptides to see whether peptide colocalize with necessary receptors for viral entry.  
Differences in viral inactivation observed may also be due to the types of in vitro 
experiments used. While both the influenza A and DENV assays used a standard plaque assay to 
measure virus inactivation, the HIV infectivity assay uses an indicator cell system as a secondary 
measure of infection. One potential problem with this difference in techniques is that it makes 
comparison between viruses difficult as the in vitro assays are not directly comparable. 
Furthermore, biological differences between each of the viruses tested may also account for 
some of the variability in activity. Depending on how the virus is grown, HIV produces as few as 
60,000 particles per infectious unit (97), whereas influenza produces an average of 40 particles 
per plaque forming units (PFU) (98) and DENV produces about 1,500 particles per PFU (99). In 
infectivity assays where there are many more non-infectious particles present, as is the case with 
HIV, it is possible that treatment peptides present are less effective since they would also be 
exerting any membrane disruptive effects on non-infectious particles as well as infectious 
particles. If there are vastly more non-infectious particles present, peptides would be less likely 
to encounter infectious particles. These differences in viral production efficiency may account 
for some of the differences observed in antiviral activity. 
One concern in designing and testing all new antimicrobial therapies is the potential 
cytotoxic effect the treatment could have against mammalian host cells. We measured the 
cytotoxic effect of our peptides using two different methods that are both standard in the field. 
First, the hemolytic effect of WLBU2 and CRAC motif containing peptides was tested in a RBC 
lysis assay to measure release of hemoglobin from peptide treated cells. All CRAC motif 
containing peptides were approximately 3-fold more hemolytic than WLBU2 alone. This assay 
  52 
was carried out on RBCs that had been isolated from donors and resuspended in PBS. However, 
in an in vivo system, RBCs would be in a more complex environment containing serum. 
Experiments have shown that AMPs have dampened cytotoxic activity in serum and whole blood 
environments and previous experiments with WLBU2 showed little peptide-induced cytotoxicity 
in whole blood (39). To determine whether serum alters cytotoxic activity of peptides, hemolysis 
assays could be carried out in the presence of serum or in whole blood, as done previously with 
WLBU2. 
CRAC motif containing peptides may be more cytolytic to RBCs because erythrocytes 
have been shown to have increased average cholesterol content in the lipid membrane as 
compared to other human cells (100). Thus, peptides containing a cholesterol targeting sequence 
would likely increase cytolytic effect on RBCs. While all blood was taken and isolated from 
healthy donors, cholesterol content of erythrocytes has been shown to be intimately linked to 
disease state (101; 102) and is sensitive to changes in plasma cholesterol levels (103). Cytolytic 
effects of CRAC motif containing peptides may not be as pronounced on other mammalian cells 
where the cholesterol content of the membrane is lower and less sensitive to circulating 
cholesterol levels. 
Cytotoxicity was also measured by MTS assay which detects oxidative processes in 
mitochondria reflected in color change by tetrazolium reduction to a formazan product that only 
occurs in metabolically active and therefore viable cells. This is a standard assay often used to 
measure cell viability, proliferation, or cytotoxicity (104). We tested a panel of cells and cell 
lines that included two transformed cell lines, a non-transformed cell line, and primary, non-
transformed cell isolates. Some increase in cytotoxicity was expected, as mammalian cells have 
regions of the membrane that are enriched for the cholesterol and could possibly attract CRAC 
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motif containing peptides. For all of the cell lines tested, CRAC motif containing peptides and 
WLBU2 displayed similar levels of cytotoxicity, with CC50 values of approximately 30 µM. 
Furthermore, we did not detect any significant differences between cytotoxicity observed on 
non-transformed and transformed cell lines. Overall, the data indicate that the addition of either 
CRAC motif to WLBU2 does not chance the cytotoxicity of peptides based on MTS assay. 
Previous research has shown that transformed and cancer cells are more susceptible to 
treatment with AMPs. Comparison of CC50 values between the transformed and non-transformed 
cell lines tested (TZM-bl, MDCK, and MRC-5) reveals no significant difference in cytotoxicity, 
contrary to what was expected. Surprisingly, PBMCs had the lowest CC50 values averaging 
about 10 µM, indicating that they were most susceptible to peptide treatment. Because these are 
primary isolates that are not an expanding population, it’s possible that they have inherently 
lower metabolic activity. Indeed, absorbance values for PBMCs in the MTS assay were always 
lower than those measured for all other cells tested following all of the same assay conditions. 
This highlights the limitations of the MTS assay as it does not directly measure the live/dead 
state of a cell, but rather whether it is metabolically active. This indirect measure of cell viability 
may not be ideal for determining direct killing of cells. Peptides may interfere with the ability of 
the tetrazoilium dye to enter cells for reduction, or there may be a direct interaction between 
components of the reduction pathway and peptides. Multiple other measures of cytotoxicity are 
possible that would help determine whether peptides induce direct killing of cells. Simple 
live/dead staining, detected by flow cytometry, may be a better way to detect cell death as the 
live/dead stain directly measures live cells versus dead cells on a cell by cell basis. 
These data indicate important properties of the CRAC motif sequence itself. Based on the 
antiviral activity and cytotoxicity data, both the LWYIK and VWYVK CRAC motifs behave 
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similarly to one another. This indicates that CRAC motifs can be designed synthetically with 
similar levels of activity to naturally occurring sequences. The results also show that addition of 
two CRAC motifs to WLBU2 does not alter activity as compared to peptides with only one 
CRAC motif, indicating that there is no additive effect with multiple CRAC motifs in the context 
of short peptide sequences. These data indicate that addition of the CRAC motif only slightly 
alters cytotoxicity, whereas peptides containing CRAC motifs are slightly more cytotoxic than 
WLBU2 alone. This is not necessarily surprising considering that mammalian cells are known to 
have regions of the membrane enriched for cholesterol that could attract CRAC motif containing 
peptides, leading to membrane disruption. 
These data, taken together, have important implications in AMP design. The pattern of 
antiviral activity observed with these peptides against the chosen panel of viruses indicates that 
the mechanism of action of AMPs against mammalian viruses may not be dependent on lipid 
exposure as currently presumed. We expected that addition of the CRAC motif would direct 
peptides to cholesterol rich viral envelopes and disrupt the membrane thereby inactivating virus. 
Viruses with greater surface lipid exposure should be more susceptible to peptide treatment 
based on this mechanism because peptides would have easier access to the envelope. Contrary to 
this hypothesis, our results indicate that viruses with less lipid surface exposure are more 
susceptible to peptide treatment. These results are interesting because they suggest that there is a 
different mechanism of antiviral activity of these peptides. Establishing what this mechanism is 
will be important in developing other peptides with greater antiviral activity, discovering 
whether viruses could develop resistance, and determining other viruses against which these 
peptides would be effective.  
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This work represents a novel approach to developing antiviral therapeutics by targeting a 
property of viral envelopes shared between many different virus families. This work indicates 
that addition of the CRAC motif to the N-terminus of WLBU2 does not significantly affect the 
antiviral activity of this peptide in some cases. In the case of HIV, addition of the CRAC motif to 
WLBU2 caused a greater enhancement of infection than that observed with WLBU2 alone. In 
the case of influenza A, addition of the CRAC motif did not significantly affect antiviral activity 
as compared to WLBU2. When peptides were tested against DENV, CRAC motif containing 
peptides were at least five fold more effective at blocking DENV infection than WLBU2 alone, 
with activity observed at sub-micromolar concentrations. We found that cytotoxicity of CRAC 
motif containing peptides was not significantly different from that WLBU2 when compared to a 
panel of transformed and non-transformed cells and cell lines by MTS assay. Further studies 
should be conducted to determine both the range of antiviral activity of WLBU2 and CRAC 
motif containing peptides as well as the mechanism of action. 
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6.0  PUBLIC HEALTH SIGNIFICANCE 
Viral diseases, including HIV, influenza, and DENV, are significant contributors to 
global disease burden. However, for most viral disease, no antiviral disease treatment exists. For 
the antiviral therapeutics that do exist, treatment is virus-specific. This work represents a novel 
antiviral strategy by targeting a characteristic shared between enveloped mammalian viruses. The 
goal of this work was to create a broadly active antiviral peptide that could be used to treat viral 
disease caused by enveloped viruses. Targeting the viral envelope for disruption is an attractive 
concept because resistance mechanisms would be extremely difficult to develop naturally. 
Further studies of the mechanism of action of CRAC motif containing peptides could allow 
development of peptides with even greater antiviral activity and reduced cytotoxicity. Antiviral 
therapies that could be used to treat multiple viral infections would significantly impact public 
health by reducing the burden of disease caused by enveloped viruses.  
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